

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-Nov-2020
 Document Type: USP Monographs
 DocId: GUID-FDEED382-612A-455B-9925-A9ED734F7329_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M20539_02_01
 DOI Ref: whv6u

© 2025 USPC
 Do not distribute

Cromolyn Sodium Inhalation Solution

DEFINITION

Cromolyn Sodium Inhalation Solution is a sterile, aqueous solution of Cromolyn Sodium. It contains NLT 90.0% and NMT 110.0% of the labeled amount of cromolyn sodium ($C_{23}H_{14}Na_2O_{11}$).

IDENTIFICATION

• **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

Add the following:

▲ **B.** The UV absorption spectrum of the major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution*, as obtained in the Assay. ▲ (USP 1-Aug-2020)

ASSAY

Change to read:

PROCEDURE

Buffer: 5.6 g/L of [monobasic potassium phosphate](#) and 22.2 g/L of [myristyltrimethylammonium bromide](#) in [water](#). Adjust with ▲ [50% sodium hydroxide TS](#) ▲ (USP 1-Aug-2020) to a pH of 6.5.

Mobile phase: [Methanol](#) and *Buffer* (55:45)

Diluent: [Acetonitrile](#) and [water](#) (30:70)

System suitability solution: 0.5 mg/mL of [USP Cromolyn Sodium RS](#) and 0.02 mg/mL each of [USP Cromolyn Related Compound A RS](#) and [USP Cromolyn Related Compound B RS](#) in *Diluent*

Standard solution: 0.5 mg/mL of [USP Cromolyn Sodium RS](#) in *Diluent*

Sample solution: Nominally equivalent to 0.5 mg/mL of cromolyn sodium from a volume of Inhalation Solution in *Diluent*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 326 nm. ▲ For *Identification B*, use a diode array detector in the range of 220–400 nm. ▲ (USP 1-Aug-2020)

Column: 4.6-mm × 10-cm; 3.5-μm packing [L7](#)

Column temperature: 40°

Flow rate: 1.5 mL/min

Injection volume: 20 μL

▲ **Run time:** NLT 2 times the retention time of cromolyn ▲ (USP 1-Aug-2020)

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—See [Table 1](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 2.0 between cromolyn related compound B and cromolyn related compound A; ▲ NLT 2.0 between cromolyn related compound A and cromolyn. ▲ (USP 1-Aug-2020) *System suitability solution*

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 0.73%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of cromolyn sodium ($C_{23}H_{14}Na_2O_{11}$) in the portion of Inhalation Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of cromolyn from the *Sample solution*

r_S = peak response of cromolyn from the *Standard solution*

C_S = concentration of [USP Cromolyn Sodium RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements

IMPURITIES

Change to read:

• ORGANIC IMPURITIES

▲ (USP 1-Aug-2020) **Mobile phase, Diluent, and System suitability solution:** Prepare as directed in the Assay.

Standard solution: 0.002 mg/mL each of [USP Cromolyn Related Compound A RS](#), [USP Cromolyn Related Compound B RS](#), and [USP Cromolyn Sodium RS](#) in *Diluent*

Sample solution: Nominally equivalent to 2 mg/mL of cromolyn sodium from a volume of Inhalation Solution in *Diluent*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 326 nm

Column: 4.6-mm × 10-cm; 3.5-μm packing [L7](#)

Temperatures

Autosampler: 4°

Column: 40°

Flow rate: 1.5 mL/min

Injection volume: 20 μL

Run time: ▲NLT▲ (USP 1-Aug-2020) 2 times the retention time of cromolyn

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—See [Table 1](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 2.0 between cromolyn related compound B and cromolyn related compound A; NLT 2.0 between cromolyn related compound A and cromolyn, *System suitability solution*

Relative standard deviation: NMT 3% for 6 replicate injections, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of cromolyn related compound A or cromolyn related compound B in the portion of Inhalation Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of cromolyn related compound A or cromolyn related compound B from the *Sample solution*

r_S = peak response of cromolyn related compound A or cromolyn related compound B from the *Standard solution*

C_S = concentration of ▲[USP Cromolyn Related Compound A RS](#) or [USP Cromolyn Related Compound B RS](#)▲ (USP 1-Aug-2020) in the *Standard solution* (mg/mL)

C_U = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Calculate the percentage of any individual unspecified degradation product in the portion of Inhalation Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each ▲individual▲ (USP 1-Aug-2020) unspecified degradation product from the *Sample solution*